Aiming to improve the FLT3/CDK inhibitory activity, novel 1H-pyrazole-3-carboxamide derivatives were also developed from compound 50 [67]. Compound 8t had a multi-kinase inhibitory capacity, by targeting KDR/VEGFR2, ERK7, FLT1, FLT4 and GSK3 in addition to FLT3 and CDKs, that was responsible for its broad activity against acute leukemia but also solid tumor models. Here, FLT3 is linked to acute leukemia.